Alisertib, which is an inhibitor of this serine/threonine kinase, demonstrated significant antiproliferative activity against GBM, especially when combined with TPI 287 and GBM stem cells, interfering with mitotic slippage in GB30 neurosphere cells [275]. The gene discussed is MARK2; the disease is glioblastoma.